Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

Hexarelin vs Tesamorelin + Ipamorelin

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

Tesamorelin + Ipamorelin has stronger documented evidence (FDA-Approved (component)) than Hexarelin (Phase 2 (not approved)) while both occupy the ghrp / gh-secretagogue classes. When clinical-evidence tier is the deciding factor, Tesamorelin + Ipamorelin is the safer pick. Hexarelin may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

Hexarelin

Phase 2 (not approved)

Tesamorelin + Ipamorelin

FDA-Approved (component)

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Side-by-side

Hexarelin Tesamorelin + Ipamorelin
Class GHRP; potent ghrelin receptor agonist FDA-approved GHRH analog (Tesamorelin) + selective GHRP (Ipamorelin) blend
Drug class Growth Hormone Secretion Growth Hormone Secretion
Mechanism GHS-R1a agonist; more potent GH release than other GHRPs Tesamorelin's trans-3-hexenoyl modification gives a longer-acting pituitary GHRH-R stimulus than CJC no-DAC, paired with Ipamorelin's GHS-R1a pulse to layer pituitary GH release. The Tesamorelin arm carries the strongest single-agent visceral-fat data (EMERALD); the Ipamorelin arm contributes pulse amplitude without cortisol/prolactin spillover.
Route SC / Intranasal SC injection
Half-life ~1 hr Tesamorelin ~26 min (plasma); Ipamorelin ~2 hrs
Dosage (research) 100-200 mcg SC 1-2x daily (short cycles) 1 mg Tesamorelin + 200 mcg Ipamorelin SC nightly (5 nights/wk). Cycle 12-16 weeks on / 4-6 weeks off
Evidence tier Phase 2 (not approved) FDA-Approved (component)
Research depth 158 indexed (PubMed 141 · CT 0 · EPMC 17) —
Availability Research Chemical Compounding Restricted
Reported risks Cortisol/prolactin elevation; pituitary desensitization Tesamorelin component carries FDA-label pancreatitis and hyperglycaemia warnings; injection-site reactions; theoretical IGF-1 elevation; cost is high (Tesamorelin compounded form is expensive)

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick Hexarelin or Tesamorelin + Ipamorelin?

Tesamorelin + Ipamorelin has stronger documented evidence (FDA-Approved (component)) than Hexarelin (Phase 2 (not approved)) while both occupy the ghrp / gh-secretagogue classes. When clinical-evidence tier is the deciding factor, Tesamorelin + Ipamorelin is the safer pick. Hexarelin may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

What is the difference between Hexarelin and Tesamorelin + Ipamorelin?

Hexarelin is classed as GHRP; potent ghrelin receptor agonist; Tesamorelin + Ipamorelin is classed as FDA-approved GHRH analog (Tesamorelin) + selective GHRP (Ipamorelin) blend. Reported mechanism: Hexarelin, GHS-R1a agonist; more potent GH release than other GHRPs; Tesamorelin + Ipamorelin, Tesamorelin's trans-3-hexenoyl modification gives a longer-acting pituitary GHRH-R stimulus than CJC no-DAC, paired with Ipamorelin's GHS-R1a pulse to layer pituitary GH release. The Tesamorelin arm carries the strongest single-agent visceral-fat data (EMERALD); the Ipamorelin arm contributes pulse amplitude without cortisol/prolactin spillover. Reported half-life: Hexarelin, ~1 hr; Tesamorelin + Ipamorelin, Tesamorelin ~26 min (plasma); Ipamorelin ~2 hrs. Routes in published studies: Hexarelin, SC / Intranasal; Tesamorelin + Ipamorelin, SC injection.

Which has stronger evidence, Hexarelin or Tesamorelin + Ipamorelin?

Tesamorelin + Ipamorelin has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Hexarelin is graded Phase 2 (not approved), with 4 cited sources on its reference page and 158 indexed studies. Tesamorelin + Ipamorelin is graded FDA-Approved (component), with 3 cited sources on its reference page.

Which is more accessible, Hexarelin or Tesamorelin + Ipamorelin?

Neither Hexarelin nor Tesamorelin + Ipamorelin is an FDA-approved drug. Catalog status: Hexarelin, Research Chemical; Tesamorelin + Ipamorelin, Compounding Restricted.

Are Hexarelin and Tesamorelin + Ipamorelin ever combined?

Hexarelin and Tesamorelin + Ipamorelin appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…